Abstract 14666: Serum Gamma-glytamyl Transferase is a Predictor of Mortality in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Background: Serum gamma-glutamyl transferase (GGT) is able to catalyse low-density lipoprotein oxidation, and associated with adverse cardiovascular outcome in patients with ischemic heart disease. However, no previous study has investigated the association between GGT and long-term mortality in patients with acute myocardial infarction (AMI). We investigated whether higher GGT levels are related with increasing mortality in AMI patients treated with drug-eluting stent (DES) implantation.
Method: A total of 2281 AMI patients undergoing percutaneous coronary intervention with the use of DES were consecutively enrolled in the COREA-AMI (Convergent Registry of cAtholic and chonnAm university for AMI) registry after the exclusion of patients with liver disease. Patients were divided into 2 groups according to normal (n=1985) or elevated levels of serum GGT (n=296). The primary clinical outcome was all-cause mortality. For validation of survival data, the vital status was obtained in 100% of patients from the Office of Statistics, Korea.
Result: Both groups showed similar demographic and angiographic characteristics. Patients with elevated serum GGT levels revealed significantly higher all-cause mortality during a median follow-up of 3-year (19.4% vs 14.7%, P=0.02). The multivariate Cox proportional hazards model identified the elevated serum GGT level as an independent correlate of long-term mortality (hazard ratio 1.5, 95% confidence interval 1.105- 2.035, p=0.009).
Conclusion: The elevated serum GGT level is an independent predictor of long-term mortality in patients with AMI treated with DES.
- © 2013 by American Heart Association, Inc.